Esomeprazole MagnesiumProton pump inhibitor CAS# 161973-10-0 |
- Lansoprazole
Catalog No.:BCC1058
CAS No.:103577-45-3
- Zinc Pyrithione
Catalog No.:BCC5008
CAS No.:13463-41-7
- Esomeprazole Sodium
Catalog No.:BCC4376
CAS No.:161796-78-7
- Esomeprazole Magnesium
Catalog No.:BCC5007
CAS No.:161973-10-0
- Lansoprazole sodium
Catalog No.:BCC4298
CAS No.:226904-00-3
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 161973-10-0 | SDF | Download SDF |
| PubChem ID | 130564 | Appearance | Powder |
| Formula | C34H36MgN6O6S2 | M.Wt | 713.12 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 125 mg/mL (175.29 mM) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | magnesium;5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide | ||
| SMILES | CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=CC(=C3)OC.CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=CC(=C3)OC.[Mg+2] | ||
| Standard InChIKey | KWORUUGOSLYAGD-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/2C17H18N3O3S.Mg/c2*1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17;/h2*5-8H,9H2,1-4H3;/q2*-1;+2 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Esomeprazole Magnesium Dilution Calculator
Esomeprazole Magnesium Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.4023 mL | 7.0114 mL | 14.0229 mL | 28.0458 mL | 35.0572 mL |
| 5 mM | 0.2805 mL | 1.4023 mL | 2.8046 mL | 5.6092 mL | 7.0114 mL |
| 10 mM | 0.1402 mL | 0.7011 mL | 1.4023 mL | 2.8046 mL | 3.5057 mL |
| 50 mM | 0.028 mL | 0.1402 mL | 0.2805 mL | 0.5609 mL | 0.7011 mL |
| 100 mM | 0.014 mL | 0.0701 mL | 0.1402 mL | 0.2805 mL | 0.3506 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Esomeprazole Magnesium (Nexium) is a proton pump inhibitor to reduce gastric acid secretion. The stability of Esomeprazole Magnesium is a function of pH; it rapidly degrades in acidic media, but it has acceptable stability under alkaline conditions. At pH
- Prehelminthosporol
Catalog No.:BCN7447
CAS No.:1619-13-2
- Segetalin A
Catalog No.:BCC9246
CAS No.:161875-97-4
- Talampanel(LY300164)
Catalog No.:BCC6378
CAS No.:161832-65-1
- Amprenavir (agenerase)
Catalog No.:BCC3619
CAS No.:161814-49-9
- Benzamil
Catalog No.:BCC7674
CAS No.:161804-20-2
- Ethyl 2-(3-cyano-4-hydroxyphenyl)-4-methyl-1,3-thiazole-5-carboxylate
Catalog No.:BCC8966
CAS No.:161798-02-3
- Ethyl 2-(3-formyl-4-hydroxyphenyl)-4-methylthiazole-5-carboxylate
Catalog No.:BCC8968
CAS No.:161798-01-2
- Ethyl 2-(4-hydroxyphenyl)-4-methylthiazole-5-carboxylate
Catalog No.:BCC8969
CAS No.:161797-99-5
- Esomeprazole Sodium
Catalog No.:BCC4376
CAS No.:161796-78-7
- Palmatrubine
Catalog No.:BCN2647
CAS No.:16176-68-4
- 12-Oxocalanolide A
Catalog No.:BCN4699
CAS No.:161753-49-7
- GLP-1 (9-36) amide
Catalog No.:BCC6001
CAS No.:161748-29-4
- Catechin pentaacetate
Catalog No.:BCN1718
CAS No.:16198-01-9
- LY2857785
Catalog No.:BCC8050
CAS No.:1619903-54-6
- GSK2801
Catalog No.:BCC6498
CAS No.:1619994-68-1
- Bromosporine
Catalog No.:BCC2226
CAS No.:1619994-69-2
- Rofecoxib
Catalog No.:BCC4437
CAS No.:162011-90-7
- UNC0379
Catalog No.:BCC8055
CAS No.:1620401-82-2
- L-371,257
Catalog No.:BCC7353
CAS No.:162042-44-6
- SC 58125
Catalog No.:BCC5948
CAS No.:162054-19-5
- Myriceric acid C
Catalog No.:BCN1719
CAS No.:162059-94-1
- Dimesna
Catalog No.:BCC1095
CAS No.:16208-51-8
- 4',4'''-Di-O-methylisochamaejasmin
Catalog No.:BCN6849
CAS No.:1620921-68-7
- SynaptoRedTM C2
Catalog No.:BCC8012
CAS No.:162112-35-8
A comparative study of the novel spectrophotometric methods versus conventional ones for the simultaneous determination of Esomeprazole magnesium trihydrate and Naproxen in their binary mixture.[Pubmed:26162342]
Spectrochim Acta A Mol Biomol Spectrosc. 2015;151:538-46.
Two novel simple, specific, accurate and precise spectrophotometric methods manipulating ratio spectra are developed and validated for simultaneous determination of Esomeprazole Magnesium trihydrate (ESO) and Naproxen (NAP) namely; absorbance subtraction and ratio difference. The results were compared to that of the conventional spectrophotometric methods namely; dual wavelength and isoabsorptive point coupled with first derivative of ratio spectra and derivative ratio. The suggested methods were validated in compliance with the ICH guidelines and were successfully applied for determination of ESO and NAP in their laboratory prepared mixtures and pharmaceutical preparation. No preliminary separation steps are required for the proposed spectrophotometeric procedures. The statistical comparison showed that there is no significant difference between the proposed methods and the reported method with respect to both accuracy and precision.
Novel naproxen/esomeprazole magnesium compound pellets based on acid-independent mechanism: in vitro and in vivo evaluation.[Pubmed:26902772]
Drug Dev Ind Pharm. 2016 Sep;42(9):1495-503.
The purpose of this study was to develop the novel naproxen/Esomeprazole Magnesium compound pellets (novel-NAP/EMZ) depending on EMZ acid-independent mechanism which has been proved to be predominate in the mechanism of co-therapy with nonsteroidal anti-inflammatory drug. The novel-NAP/EMZ compound pellets, composed of NAP colon-specific pellets (NAP-CSPs) and EMZ modified-release pellets (EMZ-MRPs), were prepared by fluid-bed coating technology with desired in vitro release profiles. The resulting pellets were filled into hard gelatin capsules for in vivo evaluation in rats and compared with the reference compound pellets, consisted of NAP enteric-coated pellets (NAP-ECPs) and EMZ immediate-release pellets (EMZ-IRPs). The reference compound pellets were prepared simulating the drug delivery system of VIMOVO((R)). In vivo pharmacokinetics, EMZ-MRPs had significantly larger AUC0-t (p < 0.01), 1.67 times more than that of EMZ-IRPs, and prolonged mean residence time (7.55 +/- 0.12 h) than that of IRPs (1.46 +/- 0.39 h). NAP-CSPs and NAP-ECPs showed similar AUC0-t. Compared to the reference compound pellets, the novel-NAP/EMZ compound pellets did not show distinct differences in histological mucosal morphology. However, biochemical tests exhibited enhanced total antioxidant capacity, increased nitric oxide content and reduced malondialdehyde level for novel-NAP/EMZ compound pellets, indicating that the acid-independent action took effect. The gastric pH values of novel-NAP/EMZ compound pellets were at a low and stable level, which could ensure normal physiological range of human gastric pH. As a result, the novel-NAP/EMZ compound pellets may be a more suitable formulation with potential advantages by improving bioavailability of drug and further reducing undesirable gastrointestinal damages.
Crystallization of Esomeprazole Magnesium Water/Butanol Solvate.[Pubmed:27120591]
Molecules. 2016 Apr 23;21(4):544.
The molecular structure of Esomeprazole Magnesium derivative in the solid-state is reported for the first time, along with a simplified crystallization pathway. The structure was determined using the single crystal X-ray diffraction technique to reveal the bonding relationships between esomeprazole heteroatoms and magnesium. The esomeprazole crystallization process was carried out in 1-butanol and water was utilized as anti-solvent. The product proved to be Esomeprazole Magnesium tetrahydrate with two 1-butanol molecules that crystallized in P6(3) space group, in a hexagonal unit cell. Complete characterization of a sample after drying was conducted by the use of powder X-ray diffraction (PXRD), (1)H-nuclear magnetic resonance (NMR), thermogravimetric analysis (TGA), differential scanning calorimetry (DSC), infrared spectroscopy (IR), and dynamic vapor sorption (DVS). Investigation by (1)H-NMR and TGA has shown that the solvent content in the dried sample consists of two water molecules and 0.3 butanol molecules per Esomeprazole Magnesium molecule. This is different from the single crystal X-ray diffraction results and can be attributed to the loss of some water and 1-butanol molecules stabilized by intermolecular interactions. The title compound, after drying, is a true solvate in terms of water; conversely, 1-butanol fills the voids of the crystal lattice in non-stoichiometric amounts.
Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO(R) (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers.[Pubmed:26257511]
Drug Des Devel Ther. 2015 Jul 31;9:4127-35.
BACKGROUND: HCP1004 is a newly developed fixed-dose combination of naproxen (500 mg) and esomeprazole strontium (20 mg) that is used in the treatment of rheumatic diseases and can reduce the risk of nonsteroidal anti-inflammatory drug-associated ulcers. The aim of this study was to evaluate the pharmacokinetics (PK) and safety of HCP1004 compared to VIMOVO((R)) (a marketed fixed-dose combination of naproxen and Esomeprazole Magnesium). SUBJECTS AND METHODS: An open-label, randomized, two-treatment, two-sequence crossover, single-dose clinical study was conducted in 70 healthy volunteers. In each period, a reference (VIMOVO((R))) or test (HCP1004) drug was administered orally, and serial blood samples for PK analysis were collected up to 72 hours after dosing. To evaluate the PK profiles, the maximum plasma concentration (Cmax) and the area under the concentration-time curve from 0 to the last measurable time (AUC0-t) were estimated using a noncompartmental method. Safety profiles were evaluated throughout the study. RESULTS: Sixty-six of the 70 subjects completed the study. The Cmax (mean +/- standard deviation) and AUC0-t (mean +/- standard deviation) for naproxen in HCP1004 were 61.67 +/- 15.16 microg/mL and 1,206.52 +/- 166.46 h . microg/mL, respectively; in VIMOVO((R)); these values were 61.85 +/- 14.54 microg/mL and 1,211.44 +/- 170.01 h . microg/mL, respectively. The Cmax and AUC0-t for esomeprazole in HCP1004 were 658.21 +/- 510.91 ng/mL and 1,109.11 +/- 1,111.59 h . ng/mL, respectively; for VIMOVO((R)), these values were 595.09 +/- 364.23 ng/mL and 1,015.12 +/- 952.98 h . ng/mL, respectively. The geometric mean ratios and 90% confidence intervals (CIs) (HCP1004 to VIMOVO((R))) of the Cmax and AUC0-t of naproxen were 0.99 (0.94-1.06) and 1.00 (0.98-1.01), respectively. For esomeprazole, the geometric mean ratios (90% CI) for the Cmax and AUC0-t were 0.99 (0.82-1.18) and 1.04 (0.91-1.18), respectively. The overall results of the safety assessment showed no clinically significant issues for either treatment. CONCLUSION: The PK of HCP1004 500/20 mg was comparable to that of VIMOVO((R)) 500/20 mg for both naproxen and esomeprazole after a single oral dose. Both drugs were well-tolerated without any safety issues.
